Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21226242 | 0.88 | MAPT (0.40) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22326643 | 0.83 | AGXT (0.44) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL14627769 | 0.83 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22548068 | 0.81 | ALDH1A1 (0.43) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22326642 | 0.81 | L3MBTL1 (0.44) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13510803 | 0.81 | ALDH1A1 (0.43) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27369629 | 0.80 | L3MBTL1 (0.47) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL678711 | 0.78 | MAPT (0.57) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL2047156 | 0.78 | NPC1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL2047154 | 0.78 | NPC1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11219214-B2 | Benzosultams and analogues and their use as fungicides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2022-01-11 | — | — | US | disclosed |
| US-20200323211-A1 | BENZOSULTAMS AND ANALOGUES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-10-15 | — | — | US | disclosed |
| US-10736321-B2 | Benzosultams and analogues and their use as fungicides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-08-11 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | JANSSEN PHARMACEUTICA NV (NL) | 2014-11-20 | — | — | US | disclosed |
| US-8828982-B2 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | RRM2B, CCNO, RRM2 | MAPT 4242/4885NPC1 636/4885RAB9A 3780/4885 |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885NPC1 636/4885RAB9A 3780/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | MAPT 3887/4885NPC1 2768/4885RAB9A 2549/4885 |
| US-20200323211-A1 | BENZOSULTAMS AND ANALOGUES AND THEIR USE AS FUNGICIDES | GABBR1, DPM1, CYP51A1 | MAPT 1384/4885NPC1 3667/4885RAB9A 3267/4885 |
| US-10736321-B2 | Benzosultams and analogues and their use as fungicides | GABBR1, DPM1, CYP51A1 | MAPT 1384/4885NPC1 3667/4885RAB9A 3267/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | MAPT 989/4885NPC1 865/4885RAB9A 2179/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | MAPT 4688/4885NPC1 484/4885RAB9A 2882/4885 |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885NPC1 636/4885RAB9A 3780/4885 |
| US-11219214-B2 | Benzosultams and analogues and their use as fungicides | GABBR1, DPM1, CYP51A1 | MAPT 1384/4885NPC1 3667/4885RAB9A 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.